IR
IR
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
17 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
IR has an insider buy conviction of 50%, compared to the Unknown sector buy average of 50%.
Multiple Insiders
P - Purchase Insiders
$0 total
Over the last 90 days, corporate insiders at IR (IR) engaged in a total of 17 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for IR shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 11.5K shares valued at $0 on Aug 3, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering IR and the Unknown sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
The Lockup Expiration Wave: Venture Capital Post-IPO Exit Strategies
A data-driven analysis of how venture capital firms and pre-IPO insiders manage lockup expirations, detailing block trade execution, distribution methods, and stock price impact.
Lock-up Expiration Frontrunning: How Venture Funds Manage Large Block Trades
When lock-up periods expire, venture funds use block trades, 10b-18 programs, and coordinated secondary offerings to exit large positions. This report reveals the strategies that minimize price impact, and how retail investors can track them.
a16z Capital Distributions vs. Open-Market Insider Buying: A 2026 Study
A 2026 empirical study comparing Andreessen Horowitz's in-kind share distributions to LPs against open-market insider purchases, revealing which signal better predicts 12-month price performance.
The Role of Venture Partners on Public Boards: Tracking a16z and Sequoia Directors
When a16z or Sequoia places a partner on a public company board, they become Section 16 insiders and must file Form 4. This report tracks VC-director trading patterns at major portfolio companies and what their transactions signal to outside investors.
FAQs About IR Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for IR.